vs
Side-by-side financial comparison of MAINZ BIOMED N.V. (MYNZ) and RenovoRx, Inc. (RNXT). Click either name above to swap in a different company.
RenovoRx, Inc. is the larger business by last-quarter revenue ($238.0K vs $214.8K, roughly 1.1× MAINZ BIOMED N.V.).
Mainz Biomed N.V. is a molecular diagnostics company specializing in the development and commercialization of non-invasive early detection tests for gastrointestinal cancers, primarily colorectal cancer. Its flagship product ColoAlert is approved and available across European markets, with active expansion initiatives targeting North America and other global regions.
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapy delivery systems for cancer treatment. Its core assets include proprietary transarterial delivery platforms, with primary operations in the United States, serving unmet medical needs in the oncology care segment.
MYNZ vs RNXT — Head-to-Head
Income Statement — Q4 FY2023 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $214.8K | $238.0K |
| Net Profit | — | $-2.9M |
| Gross Margin | 62.7% | 88.2% |
| Operating Margin | — | -1479.8% |
| Net Margin | — | -1235.7% |
| Revenue YoY | — | — |
| Net Profit YoY | — | -2.2% |
| EPS (diluted) | — | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $238.0K | ||
| Q3 25 | — | $266.0K | ||
| Q2 25 | — | $422.0K | ||
| Q1 25 | — | $197.0K | ||
| Q4 23 | $214.8K | — | ||
| Q3 23 | $181.7K | — | ||
| Q2 23 | $248.9K | — | ||
| Q1 23 | $1 | — |
| Q4 25 | — | $-2.9M | ||
| Q3 25 | — | $-2.9M | ||
| Q2 25 | — | $-2.9M | ||
| Q1 25 | — | $-2.4M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-6.3M | — | ||
| Q2 23 | $-8.3M | — | ||
| Q1 23 | $-6.6M | — |
| Q4 25 | — | 88.2% | ||
| Q3 25 | — | 80.1% | ||
| Q2 25 | — | 64.0% | ||
| Q1 25 | — | 52.3% | ||
| Q4 23 | 62.7% | — | ||
| Q3 23 | 48.0% | — | ||
| Q2 23 | 59.8% | — | ||
| Q1 23 | — | — |
| Q4 25 | — | -1479.8% | ||
| Q3 25 | — | -1203.0% | ||
| Q2 25 | — | -634.6% | ||
| Q1 25 | — | -1578.7% | ||
| Q4 23 | — | — | ||
| Q3 23 | -3104.9% | — | ||
| Q2 23 | -3183.9% | — | ||
| Q1 23 | -648755600.0% | — |
| Q4 25 | — | -1235.7% | ||
| Q3 25 | — | -1094.7% | ||
| Q2 25 | — | -686.0% | ||
| Q1 25 | — | -1228.4% | ||
| Q4 23 | — | — | ||
| Q3 23 | -3467.7% | — | ||
| Q2 23 | -3314.7% | — | ||
| Q1 23 | -656091600.0% | — |
| Q4 25 | — | $-0.08 | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | — | $-0.08 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 23 | — | — | ||
| Q3 23 | $-0.39 | — | ||
| Q2 23 | $-0.56 | — | ||
| Q1 23 | $-0.45 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1M | $7.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.4M | $5.4M |
| Total Assets | $15.4M | $8.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.0M | ||
| Q3 25 | — | $10.0M | ||
| Q2 25 | — | $12.3M | ||
| Q1 25 | — | $14.6M | ||
| Q4 23 | $7.1M | — | ||
| Q3 23 | $9.3M | — | ||
| Q2 23 | $10.9M | — | ||
| Q1 23 | $10.9M | — |
| Q4 25 | — | $5.4M | ||
| Q3 25 | — | $8.1M | ||
| Q2 25 | — | $10.6M | ||
| Q1 25 | — | $13.2M | ||
| Q4 23 | $3.4M | — | ||
| Q3 23 | $3.4M | — | ||
| Q2 23 | $5.2M | — | ||
| Q1 23 | $9.7M | — |
| Q4 25 | — | $8.1M | ||
| Q3 25 | — | $11.2M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $16.0M | ||
| Q4 23 | $15.4M | — | ||
| Q3 23 | $17.9M | — | ||
| Q2 23 | $19.3M | — | ||
| Q1 23 | $19.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-21.9M | $-3.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-3.0M | ||
| Q3 25 | — | $-2.3M | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | — | $-3.4M | ||
| Q4 23 | $-21.9M | — | ||
| Q3 23 | $-6.5M | — | ||
| Q2 23 | $-5.1M | — | ||
| Q1 23 | $-5.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-3.4M | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -1717.3% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 1.0% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
